Bluebird Bio (BLUE) priced an offering of 9.09 million shares of its common stock at $55 each, the company said late on Monday.
A First Glance at This Hedge Fund Firm’s Strategic Q2 Moves in Biotech Sector
Here’s a Running Tab of Updates Which We Find Most Relevant
Ocular Therapeutix Inc Ocular Therapeutix Inc (NASDAQ:OCUL) investors seem to be concerned with the company’s future following the news that Antony Mattessich will succeed Dr. …
Cowen analyst Eric Schmidt is out today with a research note on shares of bluebird bio Inc (NASDAQ:BLUE), following updated data from the company’s Phase …
bluebird bio Inc (NASDAQ:BLUE) and apceth Biopharma announced today that they have entered into a strategic manufacturing agreement providing for the future European …
bluebird bio Inc (NASDAQ: BLUE) announced treatment of the first patient in Northstar-2, the Phase 3 study of its LentiGlobin drug product in …
During last week’s American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, bluebird bio Inc (NASDAQ:BLUE) provided clinical updates on …
bluebird bio Inc (NASDAQ:BLUE) announced the pricing of an underwritten public offering of 3,289,473 shares of its common stock at a public offering …
bluebird bio Inc (NASDAQ:BLUE) announced that it has commenced an underwritten public offering of $200 million of its common stock. bluebird bio also …